{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:49:13Z","timestamp":1789526953531,"version":"build-2803163510"},"reference-count":83,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CEPI","award":["OAICE-031-2019"],"award-info":[{"award-number":["OAICE-031-2019"]}]},{"name":"Graduate School of Production Ecology &amp; Resource Conservation (PE&amp;RC)","award":["OAICE-031-2019"],"award-info":[{"award-number":["OAICE-031-2019"]}]},{"name":"Universidad de Costa Rica","award":["OAICE-031-2019"],"award-info":[{"award-number":["OAICE-031-2019"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Live-attenuated Rift Valley fever (RVF) vaccines transiently replicate in the vaccinated host, thereby effectively initiating an innate and adaptive immune response. Rift Valley fever virus (RVFV)-specific neutralizing antibodies are considered the main correlate of protection. Vaccination with classical live-attenuated RVF vaccines during gestation in livestock has been associated with fetal malformations, stillbirths, and fetal demise. Facilitated by an increased understanding of the RVFV infection and replication cycle and availability of reverse genetics systems, novel rationally-designed live-attenuated candidate RVF vaccines with improved safety profiles have been developed. Several of these experimental vaccines are currently advancing beyond the proof-of-concept phase and are being evaluated for application in both animals and humans. We here provide perspectives on some of these next-generation live-attenuated RVF vaccines and highlight the opportunities and challenges of these approaches to improve global health.<\/jats:p>","DOI":"10.3390\/vaccines11030707","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T07:46:43Z","timestamp":1679471203000},"page":"707","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Perspectives of Next-Generation Live-Attenuated Rift Valley Fever Vaccines for Animal and Human Use"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9790-2438","authenticated-orcid":false,"given":"Paul J.","family":"Wichgers Schreur","sequence":"first","affiliation":[{"name":"Department of Virology and Molecular Biology, Wageningen Bioveterinary Research, Wageningen University & Research, 8221 RA Lelystad, The Netherlands"},{"name":"BunyaVax B.V., 8221 RA Lelystad, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian H.","family":"Bird","sequence":"additional","affiliation":[{"name":"One Health Institute, School of Veterinary Medicine, University of California, Davis, CA 95616, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8318-2783","authenticated-orcid":false,"given":"Tetsuro","family":"Ikegami","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA"},{"name":"The Sealy Institute for Vaccine Sciences, The University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA"},{"name":"The Center for Biodefense and Emerging Infectious Diseases, The University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick","family":"Berm\u00fadez-M\u00e9ndez","sequence":"additional","affiliation":[{"name":"Department of Virology and Molecular Biology, Wageningen Bioveterinary Research, Wageningen University & Research, 8221 RA Lelystad, The Netherlands"},{"name":"Laboratory of Virology, Wageningen University & Research, 6708 PB Wageningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Kortekaas","sequence":"additional","affiliation":[{"name":"Department of Virology and Molecular Biology, Wageningen Bioveterinary Research, Wageningen University & Research, 8221 RA Lelystad, The Netherlands"},{"name":"Laboratory of Virology, Wageningen University & Research, 6708 PB Wageningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12941-020-0346-5","article-title":"The challenging management of Rift Valley Fever in humans: Literature review of the clinical disease and algorithm proposal","volume":"19","author":"Javelle","year":"2020","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e006623","DOI":"10.1136\/bmjgh-2021-006623","article-title":"Scoping future outbreaks: A scoping review on the outbreak prediction of the WHO Blueprint list of priority diseases","volume":"6","author":"Jonkmans","year":"2021","journal-title":"BMJ Glob. Health"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1099\/jgv.0.000765","article-title":"Rift Valley fever virus: Strategies for maintenance, survival and vertical transmission in mosquitoes","volume":"98","author":"Lumley","year":"2017","journal-title":"J. Gen. Virol."},{"key":"ref_4","first-page":"1","article-title":"Rift Valley fever; the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine","volume":"30","author":"Smithburn","year":"1949","journal-title":"Br. J. Exp. Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/jmv.20624","article-title":"Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine","volume":"78","author":"Botros","year":"2006","journal-title":"J. Med. Virol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1743-422X-6-94","article-title":"Pathological studies on postvaccinal reactions of Rift Valley fever in goats","volume":"6","author":"Kamal","year":"2009","journal-title":"Virol. J."},{"key":"ref_7","first-page":"119","article-title":"Hydrops amnii in sheep associated with hydranencephaly and arthrogryposis with wesselsbron disease and rift valley fever viruses as aetiological agents","volume":"44","author":"Coetzer","year":"1977","journal-title":"Onderstepoort J. Vet. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1016\/j.vaccine.2010.04.085","article-title":"Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep","volume":"28","author":"Dungu","year":"2010","journal-title":"Vaccine"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Makoschey, B., van Kilsdonk, E., Hubers, W.R., Vrijenhoek, M.P., Smit, M., Wichgers Schreur, P.J., Kortekaas, J., and Moulin, V. (2016). Rift Valley Fever Vaccine Virus Clone 13 Is Able to Cross the Ovine Placental Barrier Associated with Foetal Infections, Malformations, and Stillbirths. PLoS Negl. Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0004550"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Faburay, B., LaBeaud, A.D., McVey, D.S., Wilson, W.C., and Richt, J.A. (2017). Current Status of Rift Valley Fever Vaccine Development. Vaccines, 5.","DOI":"10.3390\/vaccines5030029"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1080\/14712598.2019.1662784","article-title":"Candidate vaccines for human Rift Valley fever","volume":"19","author":"Ikegami","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1016\/j.vaccine.2017.04.085","article-title":"Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology","volume":"35","author":"Gilbert","year":"2017","journal-title":"Vaccine"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Kitandwe, P.K., McKay, P.F., Kaleebu, P., and Shattock, R.J. (2022). An Overview of Rift Valley Fever Vaccine Development Strategies. Vaccines, 10.","DOI":"10.3390\/vaccines10111794"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e02004-20","DOI":"10.1128\/JVI.02004-20","article-title":"Development of a Simian RNA Polymerase I Promoter-Driven Reverse Genetics for the Rescue of Recombinant Rift Valley Fever Virus from Vero Cells","volume":"95","author":"Ikegami","year":"2021","journal-title":"J. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1128\/JVI.80.6.2933-2940.2006","article-title":"Rescue of infectious rift valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene","volume":"80","author":"Ikegami","year":"2006","journal-title":"J. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.virol.2006.09.035","article-title":"The NSm proteins of Rift Valley fever virus are dispensable for maturation, replication and infection","volume":"359","author":"Gerrard","year":"2007","journal-title":"Virology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"771934","DOI":"10.3389\/fmicb.2021.771934","article-title":"Recent Advances in Bunyavirus Reverse Genetics Research: Systems Development, Applications, and Future Perspectives","volume":"12","author":"Ren","year":"2021","journal-title":"Front. Microbiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12985-016-0573-8","article-title":"Rift Valley fever virus NSs protein functions and the similarity to other bunyavirus NSs proteins","volume":"13","author":"Ly","year":"2016","journal-title":"Virol. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1128\/JVI.02255-10","article-title":"NSs protein of rift valley fever virus promotes posttranslational downregulation of the TFIIH subunit p62","volume":"85","author":"Kalveram","year":"2011","journal-title":"J. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"11333","DOI":"10.1128\/JVI.01549-12","article-title":"Large-scale chromatin immunoprecipitation with promoter sequence microarray analysis of the interaction of the NSs protein of Rift Valley fever virus with regulatory DNA regions of the host genome","volume":"86","author":"Benferhat","year":"2012","journal-title":"J. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1038\/s41467-020-17101-y","article-title":"NSs amyloid formation is associated with the virulence of Rift Valley fever virus in mice","volume":"11","author":"Leger","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1128\/JVI.02501-07","article-title":"Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals","volume":"82","author":"Bird","year":"2008","journal-title":"J. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"12901","DOI":"10.1128\/JVI.06046-11","article-title":"Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep","volume":"85","author":"Bird","year":"2011","journal-title":"J. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1128\/JVI.75.3.1371-1377.2001","article-title":"Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs","volume":"75","author":"Bouloy","year":"2001","journal-title":"J. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Leventhal, S.S., Wilson, D., Feldmann, H., and Hawman, D.W. (2021). A Look into Bunyavirales Genomes: Functions of Non-Structural (NS) Proteins. Viruses, 13.","DOI":"10.3390\/v13020314"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Crabtree, M.B., Kent Crockett, R.J., Bird, B.H., Nichol, S.T., Erickson, B.R., Biggerstaff, B.J., Horiuchi, K., and Miller, B.R. (2012). Infection and transmission of Rift Valley fever viruses lacking the NSs and\/or NSm genes in mosquitoes: Potential role for NSm in mosquito infection. PLoS Negl. Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001639"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"13335","DOI":"10.1128\/JVI.01238-07","article-title":"NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis","volume":"81","author":"Won","year":"2007","journal-title":"J. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1038\/emi.2014.71","article-title":"The Rift Valley fever accessory proteins NSm and P78\/NSm-GN are distinct determinants of virus propagation in vertebrate and invertebrate hosts","volume":"3","author":"Kreher","year":"2014","journal-title":"Emerg. Microbes Infect."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Kading, R.C., Crabtree, M.B., Bird, B.H., Nichol, S.T., Erickson, B.R., Horiuchi, K., Biggerstaff, B.J., and Miller, B.R. (2014). Deletion of the NSm virulence gene of Rift Valley fever virus inhibits virus replication in and dissemination from the midgut of Aedes aegypti mosquitoes. PLoS Negl. Trop. Dis., 8.","DOI":"10.1371\/journal.pntd.0002670"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Terasaki, K., Kalveram, B., Johnson, K.N., Juelich, T., Smith, J.K., Zhang, L., Freiberg, A.N., and Makino, S. (2021). Rift Valley fever virus 78kDa envelope protein attenuates virus replication in macrophage-derived cell lines and viral virulence in mice. PLoS Negl. Trop. Dis., 15.","DOI":"10.1371\/journal.pntd.0009785"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e0042921","DOI":"10.1128\/JVI.00429-21","article-title":"Characterization of the Molecular Interactions That Govern the Packaging of Viral RNA Segments into Rift Valley Fever Phlebovirus Particles","volume":"95","author":"Tercero","year":"2021","journal-title":"J. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Piper, M.E., Sorenson, D.R., and Gerrard, S.R. (2011). Efficient cellular release of Rift Valley fever virus requires genomic RNA. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018070"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s42003-021-01821-y","article-title":"Visualizing the ribonucleoprotein content of single bunyavirus virions reveals more efficient genome packaging in the arthropod host","volume":"4","author":"Katrukha","year":"2021","journal-title":"Commun. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.coviro.2018.08.011","article-title":"Genome packaging of the Bunyavirales","volume":"33","author":"Kormelink","year":"2018","journal-title":"Curr. Opin. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Wichgers Schreur, P.J., and Kortekaas, J. (2016). Single-Molecule FISH Reveals Non-selective Packaging of Rift Valley Fever Virus Genome Segments. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005800"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Berm\u00fadez-M\u00e9ndez, E., Bronsvoort, K.F., Zwart, M.P., van de Water, S., C\u00e1rdenas-Rey, I., Vloet, R.P.M., Koenraadt, C.J.M., Pijlman, G.P., Kortekaas, J., and Wichgers Schreur, P.J. (2022). Incomplete bunyavirus particles can cooperatively support virus infection and spread. PLoS Biol., 20.","DOI":"10.1371\/journal.pbio.3001870"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Gommet, C., Billecocq, A., Jouvion, G., Hasan, M., Zaverucha do Valle, T., Guillemot, L., Blanchet, C., van Rooijen, N., Montagutelli, X., and Bouloy, M. (2011). Tissue tropism and target cells of NSs-deleted rift valley fever virus in live immunodeficient mice. PLoS Negl. Trop. Dis., 5.","DOI":"10.1371\/journal.pntd.0001421"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Borrego, B., Moreno, S., de la Losa, N., Weber, F., and Brun, A. (2021). The Change P82L in the Rift Valley Fever Virus NSs Protein Confers Attenuation in Mice. Viruses, 13.","DOI":"10.20944\/preprints202101.0439.v1"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"10310","DOI":"10.1128\/JVI.05252-11","article-title":"Creation of a recombinant Rift Valley fever virus with a two-segmented genome","volume":"85","author":"Brennan","year":"2011","journal-title":"J. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Brennan, B., Welch, S.R., and Elliott, R.M. (2014). The consequences of reconfiguring the ambisense S genome segment of Rift Valley fever virus on viral replication in mammalian and mosquito cells and for genome packaging. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1003922"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"10883","DOI":"10.1128\/JVI.00961-14","article-title":"Creation of Rift Valley fever viruses with four-segmented genomes reveals flexibility in bunyavirus genome packaging","volume":"88","author":"Oreshkova","year":"2014","journal-title":"J. Virol."},{"key":"ref_42","first-page":"95","article-title":"Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep","volume":"69","author":"Hunter","year":"2002","journal-title":"Onderstepoort J. Vet. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0264-410X(91)90314-V","article-title":"Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep","volume":"9","author":"Morrill","year":"1991","journal-title":"Vaccine"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.vetmic.2014.04.007","article-title":"Evaluation of lamb and calf responses to Rift Valley fever MP-12 vaccination","volume":"172","author":"Wilson","year":"2014","journal-title":"Vet. Microbiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.vaccine.2015.12.030","article-title":"Safety and immunogenicity of a mutagenized, live attenuated Rift Valley fever vaccine, MP-12, in a Phase 1 dose escalation and route comparison study in humans","volume":"34","author":"Pittman","year":"2016","journal-title":"Vaccine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.vaccine.2015.11.078","article-title":"Rift Valley fever MP-12 vaccine Phase 2 clinical trial: Safety, immunogenicity, and genetic characterization of virus isolates","volume":"34","author":"Pittman","year":"2016","journal-title":"Vaccine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"7262","DOI":"10.1128\/JVI.00135-15","article-title":"Rift Valley Fever Virus MP-12 Vaccine Is Fully Attenuated by a Combination of Partial Attenuations in the S, M, and L Segments","volume":"89","author":"Ikegami","year":"2015","journal-title":"J. Virol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1128\/JVI.02241-15","article-title":"The L, M, and S Segments of Rift Valley Fever Virus MP-12 Vaccine Independently Contribute to a Temperature-Sensitive Phenotype","volume":"90","author":"Nishiyama","year":"2016","journal-title":"J. Virol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41541-017-0021-9","article-title":"Genetic stability of Rift Valley fever virus MP-12 vaccine during serial passages in culture cells","volume":"2","author":"Lokugamage","year":"2017","journal-title":"NPJ Vaccines"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1128\/CVI.00114-15","article-title":"Evaluation of the Efficacy, Potential for Vector Transmission, and Duration of Immunity of MP-12, an Attenuated Rift Valley Fever Virus Vaccine Candidate, in Sheep","volume":"22","author":"Miller","year":"2015","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4269\/ajtmh.1991.44.278","article-title":"Potential for mosquito transmission of attenuated strains of Rift Valley fever virus","volume":"44","author":"Turell","year":"1991","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"100060","DOI":"10.1016\/j.jvacx.2020.100060","article-title":"Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile","volume":"5","author":"Monath","year":"2020","journal-title":"Vaccine X"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/14760584.2017.1321482","article-title":"Rift Valley fever vaccines: An overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate","volume":"16","author":"Ikegami","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1089\/vim.2022.0104","article-title":"Immunogenicity of a Candidate Live Attenuated Vaccine for Rift Valley Fever Virus with a Two-Segmented Genome","volume":"36","author":"Ayers","year":"2022","journal-title":"Viral Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.vaccine.2013.12.064","article-title":"Efficacy of a recombinant Rift Valley fever virus MP-12 with NSm deletion as a vaccine candidate in sheep","volume":"32","author":"Weingartl","year":"2014","journal-title":"Vaccine"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1016\/j.vaccine.2013.08.003","article-title":"Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves","volume":"31","author":"Morrill","year":"2013","journal-title":"Vaccine"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.vaccine.2012.10.118","article-title":"Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep","volume":"31","author":"Morrill","year":"2013","journal-title":"Vaccine"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"100070","DOI":"10.1016\/j.jvacx.2020.100070","article-title":"Safety and immunogenicity of the Rift Valley fever arMP-12 DeltaNSm21\/384 candidate vaccine in pregnant ewes","volume":"6","author":"Boumart","year":"2020","journal-title":"Vaccine X"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41541-022-00536-3","article-title":"Evaluations of rationally designed rift valley fever vaccine candidate RVax-1 in mosquito and rodent models","volume":"7","author":"Ikegami","year":"2022","journal-title":"NPJ Vaccines"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"6634","DOI":"10.1016\/j.vaccine.2017.10.036","article-title":"Attenuation and protective efficacy of Rift Valley fever phlebovirus rMP12-GM50 strain","volume":"35","author":"Ly","year":"2017","journal-title":"Vaccine"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Breiman, R.F., Njenga, M.K., Cleaveland, S., Sharif, S.K., Mbabu, M., and King, L. (2008). Lessons from the 2006\u20132007 Rift Valley fever outbreak in East Africa: Implications for prevention of emerging infectious diseases. Future Virol., 3.","DOI":"10.2217\/17460794.3.5.411"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Smith, D.R., Johnston, S.C., Piper, A., Botto, M., Donnelly, G., Shamblin, J., Albarino, C.G., Hensley, L.E., Schmaljohn, C., and Nichol, S.T. (2018). Attenuation and efficacy of live-attenuated Rift Valley fever virus vaccine candidates in non-human primates. PLoS Negl. Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006474"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2460\/javma.234.7.883","article-title":"Rift Valley fever virus","volume":"234","author":"Bird","year":"2009","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1111\/tbed.14415","article-title":"Safety study of Rift Valley Fever human vaccine candidate (DDvax) in mosquitoes","volume":"69","author":"Campbell","year":"2022","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41541-020-00212-4","article-title":"Safety and efficacy of four-segmented Rift Valley fever virus in young sheep, goats and cattle","volume":"5","author":"Oreshkova","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.vaccine.2017.04.024","article-title":"Four-segmented Rift Valley fever virus-based vaccines can be applied safely in ewes during pregnancy","volume":"35","author":"Kant","year":"2017","journal-title":"Vaccine"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41541-022-00476-y","article-title":"Safety and immunogenicity of four-segmented Rift Valley fever virus in the common marmoset","volume":"7","author":"Mooij","year":"2022","journal-title":"NPJ Vaccines"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41541-020-00271-7","article-title":"A single vaccination with four-segmented rift valley fever virus prevents vertical transmission of the wild-type virus in pregnant ewes","volume":"6","author":"Oymans","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_69","unstructured":"FDA (2023, February 01). Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/characterization-and-qualification-cell-substrates-and-other-biological-materials-used-production."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.biologicals.2020.06.002","article-title":"Report of the second international conference on next generation sequencing for adventitious virus detection in biologics for humans and animals","volume":"67","author":"Khan","year":"2020","journal-title":"Biologicals"},{"key":"ref_71","unstructured":"WHO (2023, February 01). Recommendations for the Evaluation of Animal Cell Cultures as Substrates for the Manufacture of Biological Medicinal Products and for the Characterization of Cell Banks, Annex 3, TRS No 978. Available online: https:\/\/www.who.int\/publications\/m\/item\/animal-cell-culture-trs-no-978-annex3."},{"key":"ref_72","unstructured":"WHO (2023, February 01). Proposed 1st International Virus Reference Standards for Adventitious Virus Detection in Biological Products by Next-Generation Sequencing (NGS) Technologies (CBER-5). Available online: https:\/\/www.who.int\/publications\/m\/item\/WHOBS2020-2394."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41467-017-02789-2","article-title":"Shielding and activation of a viral membrane fusion protein","volume":"9","author":"Halldorsson","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e52716","DOI":"10.7554\/eLife.52716","article-title":"Multimeric single-domain antibody complexes protect against bunyavirus infections","volume":"9","author":"Harmsen","year":"2020","journal-title":"eLife"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"E7564","DOI":"10.1073\/pnas.1705176114","article-title":"Structures of phlebovirus glycoprotein Gn and identification of a neutralizing antibody epitope","volume":"114","author":"Wu","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1016\/j.celrep.2018.12.001","article-title":"A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus","volume":"25","author":"Allen","year":"2018","journal-title":"Cell Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jviromet.2017.06.001","article-title":"A novel highly sensitive, rapid and safe Rift Valley fever virus neutralization test","volume":"248","author":"Paweska","year":"2017","journal-title":"J. Virol. Methods"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41541-022-00551-4","article-title":"Immune correlates of protection following Rift Valley fever virus vaccination","volume":"7","author":"Doyle","year":"2022","journal-title":"NPJ Vaccines"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/1743-422X-6-125","article-title":"Development of a RVFV ELISA that can distinguish infected from vaccinated animals","volume":"6","author":"McElroy","year":"2009","journal-title":"Virol. J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1128\/CVI.05420-11","article-title":"The nonstructural protein NSs induces a variable antibody response in domestic ruminants naturally infected with Rift Valley fever virus","volume":"19","author":"Fernandez","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_81","unstructured":"WHO (2023, February 01). Target Product Profiles for Rift Valley Fever Virus Vaccines. Available online: https:\/\/www.who.int\/docs\/default-source\/blue-print\/call-for-comments\/tpp-rift-valley-fever-vaccines-draft3-0pc.pdf?sfvrsn=f2f3b314_2."},{"key":"ref_82","unstructured":"WHO (2023, February 01). WHO\u2014Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control). Available online: https:\/\/extranet.who.int\/pqweb\/vector-control-products."},{"key":"ref_83","unstructured":"EMA (2023, February 01). Veterinary Limited Markets. Available online: https:\/\/www.ema.europa.eu\/en\/veterinary-regulatory\/research-development\/veterinary-limited-markets-0."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/3\/707\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:00:06Z","timestamp":1760122806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/3\/707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":83,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["vaccines11030707"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11030707","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,21]]}}}